Navigation Links
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
Date:6/9/2008

Potential Efficacy in Huntington's Disease Already Demonstrated

NOVATO, Calif., June 9 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that the U.S. Food and Drug Administration ("FDA") has granted orphan drug designation for cysteamine bitartrate ("cysteamine") for the treatment of Huntington's disease ("HD"). Cysteamine is currently approved by the FDA and European Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), a rare lysosomal storage disease. Preclinical results suggest that cysteamine has neuroprotective effects that could potentially help treat HD. Raptor's clinical development subsidiary, Bennu Pharmaceuticals Inc. ("Bennu"), plans to evaluate cysteamine in patients with HD.

HD is a rare and hereditary neurological disease thought to occur in approximately 1 out of every 20,000 people resulting in around 20,000 patients in the U.S. presently. There is currently no drug available that targets the unique molecular defect that is believed to cause HD, a progressive disease that often leads to death within 15 to 20 years after diagnosis. HD is caused by a defective gene resulting in the degeneration of certain nerve cells in the brain. The disease is characterized by uncontrollable movements and mood swings or depression, followed by dementia. Preclinical findings on cysteamine's mechanism of action suggest that it has neuroprotective effects by increasing the levels of BDNF, a neuroprotective neurotrophic factor, in the brain of HD mice. BDNF levels may also be a potential biomarker of efficacy for cysteamine in HD, an important development issue when a therapy is used to prevent or slow clinical manifestation of a disorder.

The 1983 Orphan Drug Act provides important economic incentives to encourage companies to develop potential therapies for the diagnosis, prevention and/or treatment of rare, serious diseases affecting 200,0
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Raptor Pharmaceuticals Acquires Orphan Clinical Program
2. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Fla. , Aug. 18, 2014 TNI ... biotechnology company pioneering the manufacturing and marketing of innovative ... that the Company is providing a second notice of ... In making the announcement, Noreen Griffin , ... you in advance for your participation in the Annual ...
(Date:8/18/2014)... 18, 2014 China is increasingly ... the clinical research industry. Clinicaltrial.gov statistics highlight the ... its aging population; a high increase in infectious ... densely populated pool of patients and a track ... positive points, China also presents challenges for the ...
(Date:8/16/2014)... 2014 Firms in the ... and advisory services to businesses, government bodies and ... services are highly diverse as operators assist a ... from geological and geophysical consulting services to risk ... past five years, the recovery of the Canadian ...
(Date:8/16/2014)... have found a way to make atomic-force microscope probes ... as small as the weight of an individual virus. ... National University (ANU), hinges on using laser beams to ... , "The level of sensitivity achieved after cooling is ... a large virus that is 100 billion times lighter ...
Breaking Biology Technology:TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 3Laser makes microscopes way cooler 2
... 17, 2010 Shire plc (LSE: SHP,NASDAQ: SHPGY ), the ... Anne Minto OBE, have been appointed to the,Shire Board of Directors with ... ... Human,Genetics at the Life Sciences Institute, University of Michigan ; an,Investigator ...
... June 17, 2010 An independent study has revealed,that Irish ... and consistent than a leading group of,international hypertension experts. , ... Conducted by the ... numerous blood pressure readings taken over a,24-hour period (known as ,Ambulatory Blood ...
... 17 OncoMed Pharmaceuticals, Inc. and Bayer Schering Pharma AG, ... develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt ... believed to play a significant role in the establishment, metastasis and ... , , ...
Cached Biology Technology:Shire plc Appoints Two New Board Directors 2Shire plc Appoints Two New Board Directors 3Shire plc Appoints Two New Board Directors 4Independent Study Reveals dabl System Leads the way in Accurate Cardiovascular Diagnosis 2Independent Study Reveals dabl System Leads the way in Accurate Cardiovascular Diagnosis 3OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 2OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 3OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 4OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 5
(Date:8/20/2014)... few years, Virginia Tech,s Wu Feng has built upon ... the "Computing in the Cloud" program, and synergistically complemented ... award from the Air Force on "big computing" for ... the National Institutes of Health on "big data" for ... "parallel computing" aspects from each grant, he was able ...
(Date:8/20/2014)... Carolina State University researchers have developed methods for electronically ... the electrical signals moths use to control those muscles. ... remotely-controlled moths, or "biobots," for use in emergency response. ... whether we can control the movement of moths for ... says Dr. Alper Bozkurt, an assistant professor of electrical ...
(Date:8/19/2014)... To improve students, chances of completing introductory biology ... Houston (UH) implemented a comprehensive student success program, ... failure. , Through a grant from the ... of Biology and Biochemistry embarked on a pilot ... for non-majors and "Introductory Biology" for science majors. ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Research paves way for development of cyborg moth 'biobots' 2University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... Management ... Solutions, ... a leader in finger-based biometric,identification and wireless public safety, announced today ... a patent for the,company,s "Biometric Identification Network Security" method., This ...
... time thinking about beer, but a group of Rice ... They,re using genetic engineering to create beer that contains ... reduce cancer and heart disease in lab animals. ... Engineered Machine (iGEM) competition Nov. 8-9 in Cambridge, Mass. ...
... and Infectious Diseases (NAID), one of the National Institutes ... of Washington (UW) to use systems biology approaches to ... response networks that are induced or altered during the ... research program will be led by Dr. Michael Katze, ...
Cached Biology News:BIO-key(R) Granted Additional Patent for Biometric Security Solution 2BIO-key(R) Granted Additional Patent for Biometric Security Solution 3Better beer: College team creating anticancer brew 2Better beer: College team creating anticancer brew 3NIAID funds studies of how SARS and bird flu evade antiviral responses 2
... easy transformation of the budding yeast, Saccharoyces ... simply by mixing a plasmid DNA and ... No complicated steps, such as centrifugation or ... particularly well suited for high-throughput transformation of ...
... The STag Purification Kits enable rapid analytical ... fusion proteins produced from appropriate vectors. Sufficient ... to 1 mg target protein under native ... with S-protein Agarose, which specifically retains STag ...
Request Info...
... Epitope: aa 16-25 of human GSK3 alpha. ... Storage: Store vial at -20 C prior to opening. ... aliquot contents and freeze at -20 C or below. ... Other Sub-Family: not assigned-Other ...
Biology Products: